OncLive Staff

In our exclusive interview, Neeraj Agarwal, MD, discusses the recent FDA approval of olaparib in homologous recombination repair–mutant metastatic castration-resistant prostate cancer.

The FDA has approved pembrolizumab (Keytruda) for patients with recurrent or metastatic cutaneous squamous cell carcinoma that is not curable by surgery or radiation.

In our exclusive interview, Everett Vokes, MD, discusses the path that led him to specialize in head and neck cancer and lung cancer, personal and professional challenges he encountered along the way, and the ultimate importance of bringing multimodality therapy to the forefront of treatment.

The FDA has approved selinexor for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL), not otherwise specified, including DLBCL arising from follicular lymphoma, after at least two lines of systemic therapy.

In our exclusive interview, Dr. Hegazi, shed light on nutrition-related issues among patients with cancer, early intervention strategies for patients who experience loss of muscle mass and function, and the use of specialized nutrients to prevent muscle degradation.

The US Food and Drug Administration has extended the indication of gemtuzumab ozogamicin (Mylotarg) for newly diagnosed CD33-positive acute myeloid leukemia to include pediatric patients 1 month and older.

In our exclusive interview, Suresh S. Ramalingam, MD, discusses the FDA approval of nivolumab plus ipilimumab for the first-line treatment of patients with metastatic non–small cell lung cancer.

In our exclusive interview, Dr. Gradishar shares the path that led him to specialize in the field of breast cancer, collective experiences that have inspired him throughout his career, and his hope for the continued transition from “shotgun medicine” to precision medicine in the field.

The FDA has approved pegfilgrastim-apgf, a biosimilar to pegfilgrastim, to decrease the incidence of infection, as manifested by febrile neutropenia, in patients with nonmyeloid malignancies receiving myelosuppressive anticancer drugs associated with a clinically significant incidence of febrile neutropenia.

Join us for a live broadcast on Wednesday, June 17, 2020 at 5 PM PST and 8 PM PST.

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

Omid Hamid, MD, highlights key abstracts in melanoma as they relate to the optimal duration and sequencing of checkpoint inhibitors, adoptive cell therapy, and subgroups of patients with mucosal melanoma and brain metastases.

This Onclive® webinar will focus on best practices and multidisciplinary approaches in the management of hepatocellular carcinoma and the impact of the COVID-19 pandemic on treatment selection in patients with HCC. Join us Thursday, June 23, 2020 at 8 PM EST.

This OncLive® webinar will focus on the delivery of cellular therapeutics, particularly chimeric antigen receptor (CAR) T- Cells in High-Risk Non-Hodgkin Lymphoma. Join us Tuesday, June 30, 2020 at 7 PM EST.

In our exclusive interview, Dr. Luke and Dr. Davar discuss the evolution of adjuvant therapy in melanoma from interferon alpha to checkpoint inhibition to targeted therapy, the potential advantages of neoadjuvant therapy, and the relative risk-benefit ratio of using these agents in the curative setting.

Mudit Chowdhary, MD, shares advice for family members living with patients with cancer, projects the long-term implications of the COVID-19 pandemic on clinical practice, provides insight on the effects of investigational treatments for patients with COVID-19, and details the protocols Rush University Medical Center has put into place to limit the spread of the virus.

The FDA has accepted a new drug application for tivozanib for the treatment of patients with relapsed/refractory renal cell carcinoma.

In our exclusive interview, Dr. Karlan shares the rewarding moments and challenges she has encountered in the cancer space as a female oncologist, pivotal research she has been spearheaded that has lasting impacts on the field, and other developments in gynecologic cancers that are poised to change the landscape forever.

The FDA has granted a Fast Track designation to CLR 131 for use as a treatment for patients with lymphoplasmacytic lymphoma/Waldenstrom macroglobulinemia.

Howard A. "Skip" Burris, III, MD, FASCO, FACP, and Stephanie L. Graff, MD, discuss how the COVID-19 pandemic has affected cancer care, the collaborative efforts made between Sarah Cannon Research Institute and HCA to increase access to investigational COVID-19 treatments, and the steps ASCO has taken to ensure its members’ professional education and well-being during this time.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

In our exclusive interview, Maria-Victoria Mateos, MD, PhD, discusses the FDA approval of the subcutaneous daratumumab formulation in multiple myeloma.

Manuel Hidalgo Medina, MD, PhD, discusses some of the exciting research presented at the 2020 ACCR Virtual Annual Meeting I.

Jennifer Litton, MD, discusses the findings from the overall survival analysis of the EMBRACA trial, the implications of these data, and the future utility of talazoparib in this space.

Bradley McGregor, MD, discusses the purpose of the guidelines, some of the main factors that influenced the recommendations in genitourinary cancers, and the impact of the pandemic on some of the most common treatment interventions such as immunotherapy, chemotherapy, and hormonal therapy, for patients with these malignancies.

Warner K. Huh, MD, discusses some of the key challenges faced in the management of gynecologic cancers in light of the COVID-19 crisis, shares some of the resources provided by the SGO COVID-19 task force, and projects what is needed to quell the pandemic, which he refers to as version of the Great Depression.

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in HRD-positive advanced ovarian cancer.

In our exclusive interview, Thomas Herzog, MD, discusses the FDA approval of the combination of olaparib (Lynparza) and bevacizumab (Avastin) as frontline maintenance therapy in advanced ovarian cancer. 

Jonathan C. Trent, MD, PhD, sheds light on the impact of COVID-19 on the treatment of rare cancers.

Nina Shah, MD and Sandy Wong, MD, discuss the predictive value of minimal residual disease and the need for treatment in a patient with smoldering multiple myeloma.